Skip to content
ClinCalc Pro
Menu
Mast Cell Stabiliser — Allergic Conjunctivitis Pregnancy: §4.6: cumulative experience with sodium cromoglicate suggests that it has no adverse effects on foetal development; however, as with all medicines, caution should be exercised during pregnancy and it should be used in pregnancy only when there is a clear need. Breast-feeding: it is not known whether sodium cromoglicate is excreted in breast milk, but on the basis of its physico-chemical properties this is considered unlikely, and there is no information to suggest any undesirable effects on the baby. Fertility: it is not known whether sodium cromoglicate has any effect on fertility.

Sodium Cromoglicate 2%

Brand names: Opticrom, Catacrom, Hay-Crom

Sodium cromoglicate 2% eye drops are a topical mast-cell stabiliser used to prevent and relieve the symptoms of allergic conjunctivitis, including seasonal (hay fever) and perennial allergic eye disease.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: One or two drops into each eye
Route: Ocular — instil into each eye
Frequency: Four times daily
eMC §4.2 (Allercrom 2% w/v Eye Drops, emc product 4136): 'Adults and Children over 6 years: One or two drops to be administered into each eye four times daily.' DURATION: the eye drops should not be used continuously for more than 14 days except on the advice of a doctor or pharmacist; the carton label and patient information leaflet state that the patient should consult a doctor or pharmacist if symptoms do not start to improve within 48 hours. ELDERLY: there is no evidence to suggest that dosage alteration is required for elderly patients. PAEDIATRIC (drop count, not a per-kg dose, so not expressed in the structured paedDose field): the SPC gives the same one-or-two-drops-four-times-daily regimen for children over 6 years; no posology is stated for children aged 6 years and under — verify any such use against a children's formulary. CONTACT LENSES (§4.4): this formulation contains benzalkonium chloride 0.1 mg/ml (4.5 micrograms per dose) as a preservative, which may be deposited in soft contact lenses — soft contact lenses should not be worn during treatment; other types of contact lens should be removed before instillation and not reinserted earlier than 15 minutes after use. Benzalkonium chloride has been reported to cause eye irritation and symptoms of dry eyes and may affect the tear film and corneal surface, so use with caution in dry eye patients and where the cornea may be compromised, and monitor patients on prolonged use. SUPERSEDES EARLIER HOLD: a previous draft of this page was held because the bundle then held only the sodium cromoglicate 100 mg/5 ml ORAL solution SPC (a different product and route). The bundle has since been re-fetched and now carries the correct 2% w/v eye drops SPC, from which this draft is taken; no oral-solution figure has been carried over.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to any of the ingredients listed in section 6.1 (§4.3)

Side effects

  • Transient stinging and burning on instillation of the drops
  • Rarely, other symptoms of local irritation
  • §4.4 additionally notes reports of bacterial keratitis associated with the use of topical ophthalmic products, and that the benzalkonium chloride preservative has been reported to cause eye irritation and symptoms of dry eyes

Interactions

  • None known — §4.5 reads 'None known.'

Clinical monograph

How it works

It stabilises sensitised conjunctival mast cells and inhibits their degranulation, reducing the release of histamine and other inflammatory mediators that cause itching, redness and watering.

Prescribing in practice

  • It works prophylactically and takes regular continued use over several days to reach full effect, so it is unsuitable as a single-dose treatment for an acute flare and should be used consistently throughout the allergy season.
  • It treats allergy, not infection, so a painful red eye with discharge or reduced vision needs reassessment.
  • Preserved formulations are incompatible with soft contact lens wear during instillation, though preservative-free options exist.

Monitoring

No laboratory monitoring is required; review symptom control and adherence to regular dosing.

Counselling the patient

  • Use the drops regularly every day, ideally starting before the season, rather than only when symptoms appear.
  • Allow several days of continuous use before judging how well it works.
  • Remove soft contact lenses before instilling preserved drops.

Evidence & guidelines

Sodium cromoglicate is a long-established, well-tolerated prophylactic treatment for allergic conjunctivitis, available over the counter and supported by the SPC and allergy guidance.

Reference: NICE CKS (Allergic Conjunctivitis 2022); SPC Opticrom; SIGN 141 (Allergic Rhinitis); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.